Personalized Follow-up for Adults With Uveal Melanoma at High Risk of Metastasis Using Liver MRI and Blood Tests for Early Detection and Monitoring

What this Trial Is About

Researchers are studying patients with uveal melanoma who are at high risk for liver metastases. The study aims to find biomarkers that can help diagnose liver metastases early and tailor follow-up care based on each patients personalized risk of relapse. This research is designed to improve monitoring and outcomes for these patients over a long period. Participants identified as high risk will undergo regular medical oncology consultations for oncological surveillance following a general disease staging. The study includes liver MRI scans every six months at a specialized center, and for patients who have undergone eye removal enucleation, blood samples are collected every six months to isolate plasma and mononucleated cells for biomarker research. Blood samples are taken at the first oncology visit, every six months for at least five years and up to ten years, at metastasis diagnosis, and during significant metastatic events such as surgery or changes in treatment response. During the study, participants will have scheduled visits every six months for imaging and blood sampling, with ongoing collection of biological samples for analysis. Researchers will track metastatic events, treatments, and biomarker correlations over up to ten years. This includes studies on lymphocytes, circulating tumor DNA, immune monitoring, and sequencing analyses, along with clinical and imaging data comparisons. The study involves continuous monitoring and evaluation of prognostic biomarkers and patient outcomes throughout the follow-up period.

Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)